https://www.321223.comnone 2026-11-10 05:20:54 daily 0.8 https://www.321223.com/xwdt/xydt/ 2026-11-10 05:20:34 daily 0.8 https://www.321223.com/xwdt/xjz/ 2026-11-10 05:20:14 daily 0.8 https://www.321223.com/xwdt/html/990.html 2026-11-10 05:19:54 daily 0.8 https://www.321223.com/xwdt/html/979.html 2026-11-10 05:19:34 daily 0.8 https://www.321223.com/xwdt/html/967.html 2026-11-10 05:19:14 daily 0.8 https://www.321223.com/xwdt/html/943.html 2026-11-10 05:18:54 daily 0.8 https://www.321223.com/xwdt/html/927.html 2026-11-10 05:18:34 daily 0.8 https://www.321223.com/xwdt/html/907.html 2026-11-10 05:18:14 daily 0.8 https://www.321223.com/xwdt/html/900.html 2026-11-10 05:17:54 daily 0.8 https://www.321223.com/xwdt/html/897.html 2026-11-10 05:17:34 daily 0.8 https://www.321223.com/xwdt/html/729.html 2026-11-10 05:17:14 daily 0.8 https://www.321223.com/xwdt/html/656.html 2026-11-10 05:16:54 daily 0.8 https://www.321223.com/xwdt/html/592.html 2026-11-10 05:16:34 daily 0.8 https://www.321223.com/xwdt/html/575.html 2026-11-10 05:16:14 daily 0.8 https://www.321223.com/xwdt/html/557.html 2026-11-10 05:15:54 daily 0.8 https://www.321223.com/xwdt/html/488.html 2026-11-10 05:15:34 daily 0.8 https://www.321223.com/xwdt/html/465.html 2026-11-10 05:15:14 daily 0.8 https://www.321223.com/xwdt/html/419.html 2026-11-10 05:14:54 daily 0.8 https://www.321223.com/xwdt/html/348.html 2026-11-10 05:14:34 daily 0.8 https://www.321223.com/xwdt/html/314.html 2026-11-10 05:14:14 daily 0.8 https://www.321223.com/xwdt/html/270.html 2026-11-10 05:13:54 daily 0.8 https://www.321223.com/xwdt/html/233.html 2026-11-10 05:13:34 daily 0.8 https://www.321223.com/xwdt/html/1310.html 2026-11-10 05:13:14 daily 0.8 https://www.321223.com/xwdt/html/1304.html 2026-11-10 05:12:54 daily 0.8 https://www.321223.com/xwdt/html/1303.html 2026-11-10 05:12:34 daily 0.8 https://www.321223.com/xwdt/html/1302.html 2026-11-10 05:12:14 daily 0.8 https://www.321223.com/xwdt/html/1301.html 2026-11-10 05:11:54 daily 0.8 https://www.321223.com/xwdt/html/1300.html 2026-11-10 05:11:34 daily 0.8 https://www.321223.com/xwdt/html/1297.html 2026-11-10 05:11:14 daily 0.8 https://www.321223.com/xwdt/html/1296.html 2026-11-10 05:10:54 daily 0.8 https://www.321223.com/xwdt/html/1295.html 2026-11-10 05:10:34 daily 0.8 https://www.321223.com/xwdt/html/1294.html 2026-11-10 05:10:14 daily 0.8 https://www.321223.com/xwdt/html/1286.html 2026-11-10 05:09:54 daily 0.8 https://www.321223.com/xwdt/html/1275.html 2026-11-10 05:09:34 daily 0.8 https://www.321223.com/xwdt/html/1274.html 2026-11-10 05:09:14 daily 0.8 https://www.321223.com/xwdt/html/1273.html 2026-11-10 05:08:54 daily 0.8 https://www.321223.com/xwdt/html/1272.html 2026-11-10 05:08:34 daily 0.8 https://www.321223.com/xwdt/html/1271.html 2026-11-10 05:08:14 daily 0.8 https://www.321223.com/xwdt/html/1270.html 2026-11-10 05:07:54 daily 0.8 https://www.321223.com/xwdt/html/1259.html 2026-11-10 05:07:34 daily 0.8 https://www.321223.com/xwdt/html/1258.html 2026-11-10 05:07:14 daily 0.8 https://www.321223.com/xwdt/html/1257.html 2026-11-10 05:06:54 daily 0.8 https://www.321223.com/xwdt/html/1256.html 2026-11-10 05:06:34 daily 0.8 https://www.321223.com/xwdt/html/1255.html 2026-11-10 05:06:14 daily 0.8 https://www.321223.com/xwdt/html/1254.html 2026-11-10 05:05:54 daily 0.8 https://www.321223.com/xwdt/html/1253.html 2026-11-10 05:05:34 daily 0.8 https://www.321223.com/xwdt/html/1251.html 2026-11-10 05:05:14 daily 0.8 https://www.321223.com/xwdt/html/1250.html 2026-11-10 05:04:54 daily 0.8 https://www.321223.com/xwdt/html/1249.html 2026-11-10 05:04:34 daily 0.8 https://www.321223.com/xwdt/html/1248.html 2026-11-10 05:04:14 daily 0.8 https://www.321223.com/xwdt/html/1247.html 2026-11-10 05:03:54 daily 0.8 https://www.321223.com/xwdt/html/1246.html 2026-11-10 05:03:34 daily 0.8 https://www.321223.com/xwdt/html/1245.html 2026-11-10 05:03:14 daily 0.8 https://www.321223.com/xwdt/html/1241.html 2026-11-10 05:02:54 daily 0.8 https://www.321223.com/xwdt/html/1240.html 2026-11-10 05:02:34 daily 0.8 https://www.321223.com/xwdt/html/1235.html 2026-11-10 05:02:14 daily 0.8 https://www.321223.com/xwdt/html/1234.html 2026-11-10 05:01:54 daily 0.8 https://www.321223.com/xwdt/html/1226.html 2026-11-10 05:01:34 daily 0.8 https://www.321223.com/xwdt/html/1225.html 2026-11-10 05:01:14 daily 0.8 https://www.321223.com/xwdt/html/1224.html 2026-11-10 05:00:54 daily 0.8 https://www.321223.com/xwdt/html/1200.html 2026-11-10 05:00:34 daily 0.8 https://www.321223.com/xwdt/html/1199.html 2026-11-10 05:00:14 daily 0.8 https://www.321223.com/xwdt/gsxw/ 2026-11-10 04:59:54 daily 0.8 https://www.321223.com/media/zyupr30a/hkex-eps_20260930_12354321_0.pdf 2026-11-10 04:59:34 daily 0.8 https://www.321223.com/media/znwhl4oq/final-2025-esmo-ct041-poster.pdf 2026-11-10 04:59:14 daily 0.8 https://www.321223.com/media/xvghsvht/2022-interim-report.pdf 2026-11-10 04:58:54 daily 0.8 https://www.321223.com/media/xmlelc50/poster_abstract-2557.pdf 2026-11-10 04:58:34 daily 0.8 https://www.321223.com/media/wsnbvqta/通用型car-t产品ct0596及ct1190b的积极临床数据.pdf 2026-11-10 04:58:14 daily 0.8 https://www.321223.com/media/wsnbvqta/ͨ����car-t��Ʒct0596��ct1190b�Ļ����ٴ�����.pdf 2026-11-10 04:57:54 daily 0.8 https://www.321223.com/media/wncfkrfb/公示件-泽沃基奥仑赛注射液使用培训和认证的医疗机构名单汇总-0720.pdf 2026-11-10 04:57:34 daily 0.8 https://www.321223.com/media/wivjdipc/2023-hy.pdf 2026-11-10 04:57:14 daily 0.8 https://www.321223.com/media/wccjzwma/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b.pdf 2026-11-10 04:56:54 daily 0.8 https://www.321223.com/media/vujmc2eu/green-application-form.pdf 2026-11-10 04:56:34 daily 0.8 https://www.321223.com/media/vtudbnl4/final-2025-asco-oral-presentation.pdf 2026-11-10 04:56:14 daily 0.8 https://www.321223.com/media/vtoc44bj/en_hkex-eps_20240909_11360644_0.pdf 2026-11-10 04:55:54 daily 0.8 https://www.321223.com/media/vbnbibn2/general_terms_and_conditions_of_purchase_carsgen_us_final_20231110.pdf 2026-11-10 04:55:34 daily 0.8 https://www.321223.com/media/ub5lsa0p/car-tcr-summit-2022-final.pdf 2026-11-10 04:55:14 daily 0.8 https://www.321223.com/media/u1wdz4jn/hkex-eps_20241210_11472656_0.pdf 2026-11-10 04:54:54 daily 0.8 https://www.321223.com/media/tz2paqen/global-offering-2-cn.pdf 2026-11-10 04:54:34 daily 0.8 https://www.321223.com/media/txzffkap/hkex-eps_20221209_10538157_0fan.pdf 2026-11-10 04:54:14 daily 0.8 https://www.321223.com/media/tu3jixci/hkex-eps_20230419_10692749_0_en.pdf 2026-11-10 04:53:54 daily 0.8 https://www.321223.com/media/t5zguoik/hkex-eps_20260930_12354322_0.pdf 2026-11-10 04:53:34 daily 0.8 https://www.321223.com/media/t5knxqvb/1751.pdf 2026-11-10 04:53:14 daily 0.8 https://www.321223.com/media/syrk40jm/final-carsgen-therapeutics-corporate-deck_oct-28.pdf 2026-11-10 04:52:54 daily 0.8 https://www.321223.com/media/suzbnpln/eha-2025-ct071-pf1164_juan-du.pdf 2026-11-10 04:52:34 daily 0.8 https://www.321223.com/media/stwjmue4/final-�Ƽ�ҩҵ��˾����-oct-13.pdf 2026-11-10 04:52:14 daily 0.8 https://www.321223.com/media/stwjmue4/final-Z6尊龙凯时药业公司介绍-oct-13.pdf 2026-11-10 04:51:54 daily 0.8 https://www.321223.com/media/rzmju0v4/ct0596-eha2026-poster-final-1.pdf 2026-11-10 04:51:34 daily 0.8 https://www.321223.com/media/rqfnslii/2024041800870_c.pdf 2026-11-10 04:51:14 daily 0.8 https://www.321223.com/media/pudgixhi/aacr-cldn18-2-poster.pdf 2026-11-10 04:50:54 daily 0.8 https://www.321223.com/media/pp2bzlw0/�Ƽ�ҩҵ2025Ͷ���߿�����.pdf 2026-11-10 04:50:34 daily 0.8 https://www.321223.com/media/pp2bzlw0/Z6尊龙凯时药业2025投资者盛开日.pdf 2026-11-10 04:50:14 daily 0.8 https://www.321223.com/media/pmglacuc/2023-hy-e.pdf 2026-11-10 04:49:54 daily 0.8 https://www.321223.com/media/pjrcksuy/global-offering.pdf 2026-11-10 04:49:34 daily 0.8 https://www.321223.com/media/oy2arfcg/poster-1056p.pdf 2026-11-10 04:49:14 daily 0.8 https://www.321223.com/media/otzepuxu/contractual-arrangements-which-are-material-contracts.pdf 2026-11-10 04:48:54 daily 0.8 https://www.321223.com/media/o3nbxckn/2022-ash.pdf 2026-11-10 04:48:34 daily 0.8 https://www.321223.com/media/o2hhwg5j/procedures-for-shareholders-to-propose-directors-en.pdf 2026-11-10 04:48:14 daily 0.8 https://www.321223.com/media/nfkjdysh/e_ham25051660ann-20250904-20250904_1323.pdf 2026-11-10 04:47:54 daily 0.8 https://www.321223.com/media/n2ih2b4l/carsgen-therapeutics-2025-investor-day.pdf 2026-11-10 04:47:34 daily 0.8 https://www.321223.com/media/mi3ppjp2/final-�Ƽ�ҩҵ��˾����-oct-28.pdf 2026-11-10 04:47:14 daily 0.8 https://www.321223.com/media/mi3ppjp2/final-Z6尊龙凯时药业公司介绍-oct-28.pdf 2026-11-10 04:46:54 daily 0.8 https://www.321223.com/media/mckjltow/2025-interim-report.pdf 2026-11-10 04:46:34 daily 0.8 https://www.321223.com/media/mbijtrcb/final-�Ƽ�ҩҵ��˾����-sept-1.pdf 2026-11-10 04:46:14 daily 0.8 https://www.321223.com/media/mbijtrcb/final-Z6尊龙凯时药业公司介绍-sept-1.pdf 2026-11-10 04:45:54 daily 0.8 https://www.321223.com/media/malcgk31/green-application-form-cn.pdf 2026-11-10 04:45:34 daily 0.8 https://www.321223.com/media/lzxm1ezb/4845_ash-poster.pdf 2026-11-10 04:45:14 daily 0.8 https://www.321223.com/media/lwmjqyw3/2821.pdf 2026-11-10 04:44:54 daily 0.8 https://www.321223.com/media/llznor0x/2023-asco-gi-poster_ab011-mono-combo-_0106final.pdf 2026-11-10 04:44:34 daily 0.8 https://www.321223.com/media/lgei54pn/global-offering-2.pdf 2026-11-10 04:44:14 daily 0.8 https://www.321223.com/media/kv3nfwei/2021-annual-report-en.pdf 2026-11-10 04:43:54 daily 0.8 https://www.321223.com/media/kuxd30iu/final-carsgen-therapeutics-corporate-deck_sept-1.pdf 2026-11-10 04:43:34 daily 0.8 https://www.321223.com/media/kolhjqpf/2022-interim-report-cn.pdf 2026-11-10 04:43:14 daily 0.8 https://www.321223.com/media/jyyh33c4/2021-esmo-ct041-oral-presentation.pdf 2026-11-10 04:42:54 daily 0.8 https://www.321223.com/media/jyvpmslq/hkex-eps_20260915_12332734_0.pdf 2026-11-10 04:42:34 daily 0.8 https://www.321223.com/media/iznib0sv/c_ham25051660ann-20250904-20250904_1325.pdf 2026-11-10 04:42:14 daily 0.8 https://www.321223.com/media/i4bdwekv/carsgen_arrangements-of-electronic-dissemination-of-corporate-communications_en.pdf 2026-11-10 04:41:54 daily 0.8 https://www.321223.com/media/hn1pbu44/2022_asco_annual_meeting_poster_14may2022.pdf 2026-11-10 04:41:34 daily 0.8 https://www.321223.com/media/hiuks2qn/ct041-cg4006-asco-2024_v3-0_20240603-1.pdf 2026-11-10 04:41:14 daily 0.8 https://www.321223.com/media/hgpk5qic/hkex-eps_20241210_11472655_0.pdf 2026-11-10 04:40:54 daily 0.8 https://www.321223.com/media/ghcj2aj4/cn_hkex-eps_20240909_11360645_0.pdf 2026-11-10 04:40:34 daily 0.8 https://www.321223.com/media/gdon4wmr/ct0596-ash-poster-20251110-for-submision.pdf 2026-11-10 04:40:14 daily 0.8 https://www.321223.com/media/g4aoe02d/公示文件-舒瑞基奥仑赛注射液使用培训和认证的医疗机构名单-0720.pdf 2026-11-10 04:39:54 daily 0.8 https://www.321223.com/media/fdyfi4ug/carsgen_arrangements-of-electronic-dissemination-of-corporate-communications_cn.pdf 2026-11-10 04:39:34 daily 0.8 https://www.321223.com/media/f5pblhde/ct053-ash-poster_-4762.pdf 2026-11-10 04:39:14 daily 0.8 https://www.321223.com/media/f1jny5l1/sitc-2023-poster.pdf 2026-11-10 04:38:54 daily 0.8 https://www.321223.com/media/eb0lckhd/2021-esmo-ct041-口头汇报.pdf 2026-11-10 04:38:34 daily 0.8 https://www.321223.com/media/eatjktro/hkex-eps_20260410_12102280_0.pdf 2026-11-10 04:38:14 daily 0.8 https://www.321223.com/media/dxnj3spj/ct0590-ash-poster_-4843.pdf 2026-11-10 04:37:54 daily 0.8 https://www.321223.com/media/djkf4urr/hkex-eps_20221209_10538156_0en.pdf 2026-11-10 04:37:34 daily 0.8 https://www.321223.com/media/caaamxan/hkex-eps_20260522_12169562_0.pdf 2026-11-10 04:37:14 daily 0.8 https://www.321223.com/media/brtijrlk/2021-annual-report.pdf 2026-11-10 04:36:54 daily 0.8 https://www.321223.com/media/brqhxcy4/2024041800869.pdf 2026-11-10 04:36:34 daily 0.8 https://www.321223.com/media/agmjug4b/final-eha2024-ppt-v2_clean_06.pdf 2026-11-10 04:36:14 daily 0.8 https://www.321223.com/media/5yod15ea/abstract-4095_ct0180_poster.pdf 2026-11-10 04:35:54 daily 0.8 https://www.321223.com/media/5owm5t4b/global-offering-cn.pdf 2026-11-10 04:35:34 daily 0.8 https://www.321223.com/media/5drbms3p/2024-annual-report-c.pdf 2026-11-10 04:35:14 daily 0.8 https://www.321223.com/media/4tejef2g/2025-interim-report-c.pdf 2026-11-10 04:34:54 daily 0.8 https://www.321223.com/media/4hyptsvx/ct1190b-ps2064_ye-1.pdf 2026-11-10 04:34:34 daily 0.8 https://www.321223.com/media/4cbfepok/hkex-eps_20260915_12332733_0.pdf 2026-11-10 04:34:14 daily 0.8 https://www.321223.com/media/3vsj00ph/2024-annual-report.pdf 2026-11-10 04:33:54 daily 0.8 https://www.321223.com/media/3bzk0o35/hkex-eps_20260522_12169561_0.pdf 2026-11-10 04:33:34 daily 0.8 https://www.321223.com/media/3byc3vpp/hkex-eps_20230419_10692750_0_hk.pdf 2026-11-10 04:33:14 daily 0.8 https://www.321223.com/media/2w4bh31e/procedures-for-shareholders-to-propose-directors-cn.pdf 2026-11-10 04:32:54 daily 0.8 https://www.321223.com/media/2rwlk1zn/final-carsgen-therapeutics-corporate-deck_oct-13.pdf 2026-11-10 04:32:34 daily 0.8 https://www.321223.com/media/2kygbdc3/final-p941_du.pdf 2026-11-10 04:32:14 daily 0.8 https://www.321223.com/media/1w1dumr5/final-ims_poster_pa-029_id-number-3173032-v2-1.pdf 2026-11-10 04:31:54 daily 0.8 https://www.321223.com/media/1s3dnn3g/blue-asco-poster-gpb-05-19-2023-final.pdf 2026-11-10 04:31:34 daily 0.8 https://www.321223.com/media/1rjd2yul/hkex-eps_20260410_12102281_0.pdf 2026-11-10 04:31:14 daily 0.8 https://www.321223.com/media/1gwa3sdq/ct041-st-02-phase-1b-cohort-a-2024-asco-gi-poster_final.pdf 2026-11-10 04:30:54 daily 0.8 https://www.321223.com/media/0yylooxm/ct071-ash-poster_-3451.pdf 2026-11-10 04:30:34 daily 0.8 https://www.321223.com/media/0klf3v3t/ct041-st-01-abs4017-poster_final.pdf 2026-11-10 04:30:14 daily 0.8 https://www.321223.com/lxwm/ 2026-11-10 04:29:54 daily 0.8 https://www.321223.com/jrwm/ 2026-11-10 04:29:34 daily 0.8 https://www.321223.com/jjfa/ 2026-11-10 04:29:14 daily 0.8 https://www.321223.com/html/web/xinwenzhongxin/shipinzhuanqu/index.html 2026-11-10 04:28:54 daily 0.8 https://www.321223.com/html/web/xinwenzhongxin/fangdaxinwen/index.html 2026-11-10 04:28:34 daily 0.8 https://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/index.html 2026-11-10 04:28:14 daily 0.8 https://www.321223.com/html/web/touziyuhezuo/shangshigongsi/index.html 2026-11-10 04:27:54 daily 0.8 https://www.321223.com/html/web/shehuizeren/zhichiguofang/index.html 2026-11-10 04:27:34 daily 0.8 https://www.321223.com/html/web/shehuizeren/yifanashui/index.html 2026-11-10 04:27:14 daily 0.8 https://www.321223.com/html/web/shehuizeren/shehuigongyi/index.html 2026-11-10 04:26:54 daily 0.8 https://www.321223.com/html/web/shehuizeren/jienenghuanbao/index.html 2026-11-10 04:26:34 daily 0.8 https://www.321223.com/html/web/shehuizeren/baozhangjiuye/index.html 2026-11-10 04:26:14 daily 0.8 https://www.321223.com/html/web/rencaifazhan/zhaopingonggao/index.html 2026-11-10 04:25:54 daily 0.8 https://www.321223.com/html/web/guanyuwomen/zuzhijiagou/index.html 2026-11-10 04:25:34 daily 0.8 https://www.321223.com/html/web/guanyuwomen/fazhanlicheng/index.html 2026-11-10 04:25:14 daily 0.8 https://www.321223.com/html/web/guanyuwomen/fangdarongyu/index.html 2026-11-10 04:24:54 daily 0.8 https://www.321223.com/html/web/guanyuwomen/fangdajianjie/index.html 2026-11-10 04:24:34 daily 0.8 https://www.321223.com/html/web/dangjianwenhua/xingfufangda/index.html 2026-11-10 04:24:14 daily 0.8 https://www.321223.com/html/web/dangjianwenhua/qiyelinian/index.html 2026-11-10 04:23:54 daily 0.8 https://www.321223.com/html/web/dangjianwenhua/dangqunhuodong/index.html 2026-11-10 04:23:34 daily 0.8 https://www.321223.com/html/web/chengyuandanwei/yiyao/index.html 2026-11-10 04:23:14 daily 0.8 https://www.321223.com/html/web/chengyuandanwei/tansu/index.html 2026-11-10 04:22:54 daily 0.8 https://www.321223.com/html/web/chengyuandanwei/shangye/index.html 2026-11-10 04:22:34 daily 0.8 https://www.321223.com/html/web/chengyuandanwei/hangkong/index.html 2026-11-10 04:22:14 daily 0.8 https://www.321223.com/html/web/chengyuandanwei/gangtie/index.html 2026-11-10 04:21:54 daily 0.8 https://www.321223.com/hk/privacy-policy/ 2026-11-10 04:21:34 daily 0.8 https://www.321223.com/hk/pipeline/ 2026-11-10 04:21:14 daily 0.8 https://www.321223.com/hk/our-approach/technologies/ 2026-11-10 04:20:54 daily 0.8 https://www.321223.com/hk/our-approach/publications/?page=1 2026-11-10 04:20:34 daily 0.8 https://www.321223.com/hk/our-approach/publications/ 2026-11-10 04:20:14 daily 0.8 https://www.321223.com/hk/our-approach/manufacturing/ 2026-11-10 04:19:54 daily 0.8 https://www.321223.com/hk/our-approach/ 2026-11-10 04:19:34 daily 0.8 https://www.321223.com/hk/news/�Ƽ�ҩҵct041����asco-�״ι�������ע���ٴ���������/ 2026-11-10 04:19:14 daily 0.8 https://www.321223.com/hk/news/?page=4 2026-11-10 04:18:54 daily 0.8 https://www.321223.com/hk/news/?page=3 2026-11-10 04:18:34 daily 0.8 https://www.321223.com/hk/news/?page=2 2026-11-10 04:18:14 daily 0.8 https://www.321223.com/hk/news/?page=1 2026-11-10 04:17:54 daily 0.8 https://www.321223.com/hk/news/20191209/ 2026-11-10 04:17:34 daily 0.8 https://www.321223.com/hk/news/20190301/ 2026-11-10 04:17:14 daily 0.8 https://www.321223.com/hk/news/20190129/ 2026-11-10 04:16:54 daily 0.8 https://www.321223.com/hk/news/20190128/ 2026-11-10 04:16:34 daily 0.8 https://www.321223.com/hk/news/20170810/ 2026-11-10 04:16:14 daily 0.8 https://www.321223.com/hk/news/ 2026-11-10 04:15:54 daily 0.8 https://www.321223.com/hk/investors/listing-documents/ 2026-11-10 04:15:34 daily 0.8 https://www.321223.com/hk/investors/ir-contact/ 2026-11-10 04:15:14 daily 0.8 https://www.321223.com/hk/investors/financial-reports/ 2026-11-10 04:14:54 daily 0.8 https://www.321223.com/hk/investors/corporate-governance/ 2026-11-10 04:14:34 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=5 2026-11-10 04:14:14 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=4 2026-11-10 04:13:54 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=3 2026-11-10 04:13:34 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=2 2026-11-10 04:13:14 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=1 2026-11-10 04:12:54 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/ 2026-11-10 04:12:34 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=5 2026-11-10 04:12:14 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=4 2026-11-10 04:11:54 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=3 2026-11-10 04:11:34 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=2 2026-11-10 04:11:14 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=1 2026-11-10 04:10:54 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/ 2026-11-10 04:10:34 daily 0.8 https://www.321223.com/hk/investors/announcements-circulars/ 2026-11-10 04:10:14 daily 0.8 https://www.321223.com/hk/investors/ 2026-11-10 04:09:54 daily 0.8 https://www.321223.com/hk/disclaimer/ 2026-11-10 04:09:34 daily 0.8 https://www.321223.com/hk/contact-us/ 2026-11-10 04:09:14 daily 0.8 https://www.321223.com/hk/careers/join-us/ 2026-11-10 04:08:54 daily 0.8 https://www.321223.com/hk/careers/ 2026-11-10 04:08:34 daily 0.8 https://www.321223.com/hk/about-us/vision-mission-values/ 2026-11-10 04:08:14 daily 0.8 https://www.321223.com/hk/about-us/partnering/ 2026-11-10 04:07:54 daily 0.8 https://www.321223.com/hk/about-us/company-overview/ 2026-11-10 04:07:34 daily 0.8 https://www.321223.com/hk/about-us/ 2026-11-10 04:07:14 daily 0.8 https://www.321223.com/hk/ 2026-11-10 04:06:54 daily 0.8 https://www.321223.com/gydk/ryzz/ 2026-11-10 04:06:34 daily 0.8 https://www.321223.com/gydk/qysl/ 2026-11-10 04:06:14 daily 0.8 https://www.321223.com/gydk/gywm/ 2026-11-10 04:05:54 daily 0.8 https://www.321223.com/en/privacy-policy/ 2026-11-10 04:05:14 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/kj-c2630/ 2026-11-10 04:04:34 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/kj-c2527/ 2026-11-10 04:03:54 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/kj-c2526/ 2026-11-10 04:03:14 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/ct1390b/ 2026-11-10 04:02:34 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/ct1190b-kj-c2219/ 2026-11-10 04:01:54 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/ct0596/ 2026-11-10 04:01:14 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/ 2026-11-10 04:00:34 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2635/ 2026-11-10 03:59:54 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2634/ 2026-11-10 03:59:14 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2633/ 2026-11-10 03:58:34 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2632/ 2026-11-10 03:57:54 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2529/ 2026-11-10 03:57:14 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/ 2026-11-10 03:56:34 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/car-t-cell-therapies/zevor-cel-ct053-3/ 2026-11-10 03:55:54 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/car-t-cell-therapies/ct041/ 2026-11-10 03:55:14 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/car-t-cell-therapies/ 2026-11-10 03:54:34 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/ 2026-11-10 03:53:54 daily 0.8 https://www.321223.com/en/pipeline/expanded-access/ 2026-11-10 03:53:14 daily 0.8 https://www.321223.com/en/pipeline/ 2026-11-10 03:52:34 daily 0.8 https://www.321223.com/en/our-approach/technologies/ 2026-11-10 03:51:54 daily 0.8 https://www.321223.com/en/our-approach/publications/zevorcabtagene-autoleucel-first-approval/ 2026-11-10 03:51:14 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-κb-icam1-signaling/ 2026-11-10 03:50:34 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-��b-icam1-signaling/ 2026-11-10 03:50:14 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=5 2026-11-10 03:49:54 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=4 2026-11-10 03:49:34 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=2 2026-11-10 03:49:14 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=1 2026-11-10 03:48:54 daily 0.8 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=4 2026-11-10 03:48:34 daily 0.8 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=2 2026-11-10 03:48:14 daily 0.8 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=1 2026-11-10 03:47:54 daily 0.8 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/ 2026-11-10 03:47:14 daily 0.8 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=5 2026-11-10 03:46:54 daily 0.8 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=4 2026-11-10 03:46:34 daily 0.8 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=2 2026-11-10 03:46:14 daily 0.8 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=1 2026-11-10 03:45:54 daily 0.8 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/ 2026-11-10 03:45:14 daily 0.8 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=5 2026-11-10 03:44:54 daily 0.8 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=4 2026-11-10 03:44:34 daily 0.8 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=2 2026-11-10 03:44:14 daily 0.8 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=1 2026-11-10 03:43:54 daily 0.8 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/ 2026-11-10 03:43:14 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=5 2026-11-10 03:42:54 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=4 2026-11-10 03:42:34 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=2 2026-11-10 03:42:14 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=1 2026-11-10 03:41:54 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/ 2026-11-10 03:41:14 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=4 2026-11-10 03:40:54 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=2 2026-11-10 03:40:34 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=1 2026-11-10 03:40:14 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/ 2026-11-10 03:39:34 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3ε-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ 2026-11-10 03:38:54 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3��-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ 2026-11-10 03:38:34 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=5 2026-11-10 03:38:14 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=4 2026-11-10 03:37:54 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=2 2026-11-10 03:37:34 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=1 2026-11-10 03:37:14 daily 0.8 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=4 2026-11-10 03:36:54 daily 0.8 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=2 2026-11-10 03:36:34 daily 0.8 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=1 2026-11-10 03:36:14 daily 0.8 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/ 2026-11-10 03:35:34 daily 0.8 https://www.321223.com/en/our-approach/publications/?page=5 2026-11-10 03:35:14 daily 0.8 https://www.321223.com/en/our-approach/publications/?page=4 2026-11-10 03:34:54 daily 0.8 https://www.321223.com/en/our-approach/publications/?page=3 2026-11-10 03:34:34 daily 0.8 https://www.321223.com/en/our-approach/publications/?page=2 2026-11-10 03:34:14 daily 0.8 https://www.321223.com/en/our-approach/publications/?page=1 2026-11-10 03:33:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20261001/ 2026-11-10 03:33:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20260918/?page=5 2026-11-10 03:32:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20260918/?page=4 2026-11-10 03:32:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20260918/?page=2 2026-11-10 03:32:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20260918/?page=1 2026-11-10 03:31:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20260918/ 2026-11-10 03:31:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20251029/?page=5 2026-11-10 03:30:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20251029/?page=4 2026-11-10 03:30:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20251029/?page=2 2026-11-10 03:29:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20251029/?page=1 2026-11-10 03:28:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20251029/ 2026-11-10 03:28:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20251008/?page=4 2026-11-10 03:27:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20251008/?page=2 2026-11-10 03:27:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20251008/?page=1 2026-11-10 03:27:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20251008/ 2026-11-10 03:26:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20250930/?page=4 2026-11-10 03:26:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20250930/?page=2 2026-11-10 03:25:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20250930/?page=1 2026-11-10 03:25:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20250930/ 2026-11-10 03:24:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20250531/?page=5 2026-11-10 03:24:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20250531/?page=4 2026-11-10 03:24:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20250531/?page=2 2026-11-10 03:23:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20250531/?page=1 2026-11-10 03:23:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20250531/ 2026-11-10 03:22:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20240524/?page=5 2026-11-10 03:22:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20240524/?page=4 2026-11-10 03:22:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20240524/?page=2 2026-11-10 03:21:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20240524/?page=1 2026-11-10 03:21:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20240524/ 2026-11-10 03:20:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20240311/?page=5 2026-11-10 03:20:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20240311/?page=4 2026-11-10 03:20:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20240311/?page=2 2026-11-10 03:19:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20240311/?page=1 2026-11-10 03:19:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20240311/ 2026-11-10 03:18:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20240205/?page=5 2026-11-10 03:18:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20240205/?page=4 2026-11-10 03:18:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20240205/?page=2 2026-11-10 03:17:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20240205/?page=1 2026-11-10 03:17:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20240205/ 2026-11-10 03:16:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20230920/?page=4 2026-11-10 03:16:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20230920/?page=2 2026-11-10 03:16:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20230920/?page=1 2026-11-10 03:15:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20230920/ 2026-11-10 03:15:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20230909/?page=5 2026-11-10 03:14:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20230909/?page=4 2026-11-10 03:14:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20230909/?page=2 2026-11-10 03:14:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20230909/?page=1 2026-11-10 03:13:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20230909/ 2026-11-10 03:13:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20230830/?page=5 2026-11-10 03:12:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20230830/?page=4 2026-11-10 03:12:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20230830/?page=2 2026-11-10 03:12:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20230830/?page=1 2026-11-10 03:11:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20230830/ 2026-11-10 03:11:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20221215/?page=4 2026-11-10 03:10:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20221215/?page=2 2026-11-10 03:10:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20221215/?page=1 2026-11-10 03:10:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20221215/ 2026-11-10 03:09:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20220817/?page=4 2026-11-10 03:09:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20220817/?page=2 2026-11-10 03:08:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20220817/?page=1 2026-11-10 03:08:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20220817/ 2026-11-10 03:07:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20201001/?page=5 2026-11-10 03:07:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20201001/?page=4 2026-11-10 03:07:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20201001/?page=2 2026-11-10 03:06:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20201001/?page=1 2026-11-10 03:06:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20201001/ 2026-11-10 03:05:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20200925/ 2026-11-10 03:05:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20200801/?page=4 2026-11-10 03:04:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20200801/?page=2 2026-11-10 03:04:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20200801/?page=1 2026-11-10 03:04:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20200801/ 2026-11-10 03:03:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20200121/?page=4 2026-11-10 03:03:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20200121/?page=2 2026-11-10 03:02:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20200121/?page=1 2026-11-10 03:02:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20200121/ 2026-11-10 03:01:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20191219/?page=4 2026-11-10 03:01:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20191219/?page=2 2026-11-10 03:01:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20191219/?page=1 2026-11-10 03:00:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20191219/ 2026-11-10 03:00:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20190920/?page=5 2026-11-10 02:59:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20190920/?page=4 2026-11-10 02:59:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20190920/?page=2 2026-11-10 02:59:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20190920/?page=1 2026-11-10 02:58:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20190920/ 2026-11-10 02:58:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20190701/?page=4 2026-11-10 02:57:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20190701/?page=2 2026-11-10 02:57:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20190701/?page=1 2026-11-10 02:57:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20190701/ 2026-11-10 02:56:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20190429/ 2026-11-10 02:55:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20190417/?page=4 2026-11-10 02:55:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20190417/?page=2 2026-11-10 02:55:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20190417/?page=1 2026-11-10 02:54:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20190417/ 2026-11-10 02:54:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20181101/?page=5 2026-11-10 02:53:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20181101/?page=4 2026-11-10 02:53:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20181101/?page=2 2026-11-10 02:53:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20181101/?page=1 2026-11-10 02:52:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20181101/ 2026-11-10 02:52:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20181001/?page=5 2026-11-10 02:51:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20181001/?page=4 2026-11-10 02:51:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20181001/?page=2 2026-11-10 02:51:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20181001/?page=1 2026-11-10 02:50:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20181001/ 2026-11-10 02:50:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20180906/ 2026-11-10 02:49:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20180804/?page=4 2026-11-10 02:49:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20180804/?page=2 2026-11-10 02:48:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20180804/?page=1 2026-11-10 02:48:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20180804/ 2026-11-10 02:47:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20171218/?page=4 2026-11-10 02:47:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20171218/?page=2 2026-11-10 02:47:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20171218/?page=1 2026-11-10 02:46:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20171218/ 2026-11-10 02:46:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20170919/?page=4 2026-11-10 02:45:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20170919/?page=2 2026-11-10 02:45:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20170919/?page=1 2026-11-10 02:45:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20170919/ 2026-11-10 02:44:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20170703/?page=5 2026-11-10 02:44:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20170703/?page=4 2026-11-10 02:43:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20170703/?page=2 2026-11-10 02:43:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20170703/?page=1 2026-11-10 02:43:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20170703/ 2026-11-10 02:42:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20170516/?page=4 2026-11-10 02:42:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20170516/?page=2 2026-11-10 02:41:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20170516/?page=1 2026-11-10 02:41:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20170516/ 2026-11-10 02:40:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20161229/?page=5 2026-11-10 02:40:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20161229/?page=4 2026-11-10 02:40:14 daily 0.8 https://www.321223.com/en/our-approach/publications/20161229/?page=2 2026-11-10 02:39:54 daily 0.8 https://www.321223.com/en/our-approach/publications/20161229/?page=1 2026-11-10 02:39:34 daily 0.8 https://www.321223.com/en/our-approach/publications/20161229/ 2026-11-10 02:38:54 daily 0.8 https://www.321223.com/en/our-approach/publications/ 2026-11-10 02:38:14 daily 0.8 https://www.321223.com/en/our-approach/manufacturing/ 2026-11-10 02:37:34 daily 0.8 https://www.321223.com/en/our-approach/ 2026-11-10 02:36:54 daily 0.8 https://www.321223.com/en/news/?page=2 2026-11-10 02:36:34 daily 0.8 https://www.321223.com/en/news/?page=13 2026-11-10 02:36:14 daily 0.8 https://www.321223.com/en/news/?page=1 2026-11-10 02:35:54 daily 0.8 https://www.321223.com/en/news/20261026/ 2026-11-10 02:35:34 daily 0.8 https://www.321223.com/en/news/20261013/ 2026-11-10 02:35:14 daily 0.8 https://www.321223.com/en/news/20260929/ 2026-11-10 02:34:54 daily 0.8 https://www.321223.com/en/news/20260819/ 2026-11-10 02:34:34 daily 0.8 https://www.321223.com/en/news/20260807/ 2026-11-10 02:34:14 daily 0.8 https://www.321223.com/en/news/20260804/ 2026-11-10 02:33:54 daily 0.8 https://www.321223.com/en/news/20260715/ 2026-11-10 02:33:34 daily 0.8 https://www.321223.com/en/news/20260622/ 2026-11-10 02:33:14 daily 0.8 https://www.321223.com/en/news/20260615/ 2026-11-10 02:32:54 daily 0.8 https://www.321223.com/en/news/20260601/ 2026-11-10 02:32:34 daily 0.8 https://www.321223.com/en/news/20260521/ 2026-11-10 02:32:14 daily 0.8 https://www.321223.com/en/news/20260512/ 2026-11-10 02:31:54 daily 0.8 https://www.321223.com/en/news/20260428/ 2026-11-10 02:31:34 daily 0.8 https://www.321223.com/en/news/20260309/ 2026-11-10 02:31:14 daily 0.8 https://www.321223.com/en/news/20260306/ 2026-11-10 02:30:54 daily 0.8 https://www.321223.com/en/news/20260213/ 2026-11-10 02:30:34 daily 0.8 https://www.321223.com/en/news/20260112/ 2026-11-10 02:30:14 daily 0.8 https://www.321223.com/en/news/20251229/ 2026-11-10 02:29:54 daily 0.8 https://www.321223.com/en/news/20250625/ 2026-11-10 02:29:34 daily 0.8 https://www.321223.com/en/news/20250120/ 2026-11-10 02:29:14 daily 0.8 https://www.321223.com/en/news/20250113/ 2026-11-10 02:28:54 daily 0.8 https://www.321223.com/en/news/20241231/ 2026-11-10 02:28:34 daily 0.8 https://www.321223.com/en/news/2023-08-21/ 2026-11-10 02:28:14 daily 0.8 https://www.321223.com/en/news/20220921/ 2026-11-10 02:27:54 daily 0.8 https://www.321223.com/en/news/20190129/ 2026-11-10 02:27:34 daily 0.8 https://www.321223.com/en/news/ 2026-11-10 02:26:54 daily 0.8 https://www.321223.com/en/investors/listing-documents/ 2026-11-10 02:26:14 daily 0.8 https://www.321223.com/en/investors/ir-contact/ 2026-11-10 02:25:34 daily 0.8 https://www.321223.com/en/investors/financial-reports/ 2026-11-10 02:24:54 daily 0.8 https://www.321223.com/en/investors/corporate-governance/ 2026-11-10 02:24:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=6 2026-11-10 02:23:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=5 2026-11-10 02:23:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=4 2026-11-10 02:23:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=3 2026-11-10 02:22:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=2 2026-11-10 02:22:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=1 2026-11-10 02:22:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/ 2026-11-10 02:21:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=6 2026-11-10 02:21:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=5 2026-11-10 02:20:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=4 2026-11-10 02:20:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=3 2026-11-10 02:20:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=2 2026-11-10 02:19:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=1 2026-11-10 02:19:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/ 2026-11-10 02:18:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=6 2026-11-10 02:18:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=5 2026-11-10 02:18:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=4 2026-11-10 02:17:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=3 2026-11-10 02:17:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=2 2026-11-10 02:17:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=1 2026-11-10 02:16:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20261026/ 2026-11-10 02:16:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=5 2026-11-10 02:15:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=4 2026-11-10 02:15:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=3 2026-11-10 02:15:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=2 2026-11-10 02:14:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=1 2026-11-10 02:14:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/ 2026-11-10 02:13:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=5 2026-11-10 02:13:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=4 2026-11-10 02:13:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=3 2026-11-10 02:12:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=2 2026-11-10 02:12:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=1 2026-11-10 02:12:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/ 2026-11-10 02:11:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=6 2026-11-10 02:11:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=5 2026-11-10 02:10:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=4 2026-11-10 02:10:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=3 2026-11-10 02:10:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=2 2026-11-10 02:09:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=1 2026-11-10 02:09:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/ 2026-11-10 02:08:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=6 2026-11-10 02:08:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=5 2026-11-10 02:08:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=4 2026-11-10 02:07:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=3 2026-11-10 02:07:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=2 2026-11-10 02:07:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=1 2026-11-10 02:06:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/ 2026-11-10 02:06:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=5 2026-11-10 02:05:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=4 2026-11-10 02:05:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=3 2026-11-10 02:05:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=2 2026-11-10 02:04:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=1 2026-11-10 02:04:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/ 2026-11-10 02:03:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 2026-11-10 02:03:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-10 02:03:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-10 02:02:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-10 02:02:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-10 02:02:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-10 02:01:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-10 02:01:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=6 2026-11-10 02:00:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=5 2026-11-10 02:00:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=4 2026-11-10 02:00:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=3 2026-11-10 01:59:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=2 2026-11-10 01:59:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=1 2026-11-10 01:59:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/ 2026-11-10 01:58:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=6 2026-11-10 01:58:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=5 2026-11-10 01:57:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=4 2026-11-10 01:57:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=3 2026-11-10 01:57:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=2 2026-11-10 01:56:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=1 2026-11-10 01:56:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/ 2026-11-10 01:55:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-asco-claudin18-2-specific-car-t-cells-satri-cel-versus-treatment-of-physician-s-choice-tpc-for-previously-treated-advanced-gastric-or-gastroesophageal-junction-cancer-g-gejc-primary-results-from-a-randomized-open-label-phase-ii-trial-c/ 2026-11-10 01:55:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=6 2026-11-10 01:54:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=5 2026-11-10 01:54:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=4 2026-11-10 01:54:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=3 2026-11-10 01:53:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=2 2026-11-10 01:53:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=1 2026-11-10 01:53:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/ 2026-11-10 01:52:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-10 01:52:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-10 01:51:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-10 01:51:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-10 01:51:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-10 01:50:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-10 01:50:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=5 2026-11-10 01:49:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=4 2026-11-10 01:49:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=3 2026-11-10 01:49:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=2 2026-11-10 01:48:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=1 2026-11-10 01:48:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/ 2026-11-10 01:47:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=5 2026-11-10 01:47:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=4 2026-11-10 01:47:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=3 2026-11-10 01:46:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=2 2026-11-10 01:46:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=1 2026-11-10 01:46:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/ 2026-11-10 01:45:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=5 2026-11-10 01:45:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=4 2026-11-10 01:44:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=3 2026-11-10 01:44:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=2 2026-11-10 01:44:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=1 2026-11-10 01:43:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/ 2026-11-10 01:43:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=6 2026-11-10 01:42:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=5 2026-11-10 01:42:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=4 2026-11-10 01:42:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=3 2026-11-10 01:41:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=2 2026-11-10 01:41:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=1 2026-11-10 01:41:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/ 2026-11-10 01:40:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/ 2026-11-10 01:39:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=6 2026-11-10 01:39:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=5 2026-11-10 01:39:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=4 2026-11-10 01:38:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=3 2026-11-10 01:38:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=2 2026-11-10 01:38:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=1 2026-11-10 01:37:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/ 2026-11-10 01:37:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=6 2026-11-10 01:36:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=5 2026-11-10 01:36:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=4 2026-11-10 01:36:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=3 2026-11-10 01:35:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=2 2026-11-10 01:35:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=1 2026-11-10 01:35:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/ 2026-11-10 01:34:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-gi-a-multicenter-phase-1-study-of-ab011-a-recombinant-humanized-anti-cldn18-2-monoclonal-antibody-ab011-as-monotherapy-and-combined-with-capecitabine-and-oxaliplatin-capox-in-patients-with-advanced-solid-tumors/ 2026-11-10 01:33:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=6 2026-11-10 01:33:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=5 2026-11-10 01:33:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=4 2026-11-10 01:32:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=3 2026-11-10 01:32:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=2 2026-11-10 01:32:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=1 2026-11-10 01:31:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/ 2026-11-10 01:31:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=5 2026-11-10 01:30:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=4 2026-11-10 01:30:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=3 2026-11-10 01:30:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=2 2026-11-10 01:29:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=1 2026-11-10 01:29:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/ 2026-11-10 01:28:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=6 2026-11-10 01:28:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=5 2026-11-10 01:28:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=4 2026-11-10 01:27:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=3 2026-11-10 01:27:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=2 2026-11-10 01:27:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=1 2026-11-10 01:26:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/ 2026-11-10 01:26:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=6 2026-11-10 01:25:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=5 2026-11-10 01:25:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=4 2026-11-10 01:25:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=3 2026-11-10 01:24:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=2 2026-11-10 01:24:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=1 2026-11-10 01:24:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/ 2026-11-10 01:23:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 2026-11-10 01:23:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-10 01:22:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-10 01:22:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-10 01:22:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-10 01:21:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-10 01:21:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-10 01:20:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=5 2026-11-10 01:20:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=4 2026-11-10 01:20:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=3 2026-11-10 01:19:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=2 2026-11-10 01:19:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=1 2026-11-10 01:19:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/ 2026-11-10 01:18:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=6 2026-11-10 01:18:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=5 2026-11-10 01:17:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=4 2026-11-10 01:17:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=3 2026-11-10 01:17:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=2 2026-11-10 01:16:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=1 2026-11-10 01:16:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/ 2026-11-10 01:15:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=6 2026-11-10 01:15:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=5 2026-11-10 01:15:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=4 2026-11-10 01:14:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=3 2026-11-10 01:14:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=2 2026-11-10 01:14:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=1 2026-11-10 01:13:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/ 2026-11-10 01:13:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=6 2026-11-10 01:12:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=5 2026-11-10 01:12:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=4 2026-11-10 01:12:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=3 2026-11-10 01:11:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=2 2026-11-10 01:11:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=1 2026-11-10 01:11:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/ 2026-11-10 01:10:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=6 2026-11-10 01:10:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=5 2026-11-10 01:09:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=4 2026-11-10 01:09:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=3 2026-11-10 01:09:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=2 2026-11-10 01:08:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=1 2026-11-10 01:08:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/ 2026-11-10 01:07:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/ 2026-11-10 01:07:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=5 2026-11-10 01:06:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=4 2026-11-10 01:06:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=3 2026-11-10 01:06:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=2 2026-11-10 01:05:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=1 2026-11-10 01:05:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/ 2026-11-10 01:05:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/?page=5 2026-11-10 01:04:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/?page=4 2026-11-10 01:04:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/?page=3 2026-11-10 01:04:14 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/?page=2 2026-11-10 01:03:54 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/?page=1 2026-11-10 01:03:34 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/ 2026-11-10 01:02:54 daily 0.8 https://www.321223.com/en/investors/announcements-circulars/ 2026-11-10 01:02:14 daily 0.8 https://www.321223.com/en/investors/ 2026-11-10 01:01:34 daily 0.8 https://www.321223.com/en/disclaimer/ 2026-11-10 01:00:54 daily 0.8 https://www.321223.com/en/contact-us/ 2026-11-10 01:00:14 daily 0.8 https://www.321223.com/en/careers/join-us/ 2026-11-10 00:59:34 daily 0.8 https://www.321223.com/en/careers/ 2026-11-10 00:58:54 daily 0.8 https://www.321223.com/en/about-us/vision-mission-values/ 2026-11-10 00:58:14 daily 0.8 https://www.321223.com/en/about-us/partnering/ 2026-11-10 00:57:34 daily 0.8 https://www.321223.com/en/about-us/leadership/ 2026-11-10 00:56:54 daily 0.8 https://www.321223.com/en/about-us/company-overview/ 2026-11-10 00:56:14 daily 0.8 https://www.321223.com/en/about-us/ 2026-11-10 00:55:34 daily 0.8 https://www.321223.com/en/" 2026-11-10 00:55:14 daily 0.8 https://www.321223.com/en/ 2026-11-10 00:54:34 daily 0.8 https://www.321223.com/cpzs/html/179.html 2026-11-10 00:54:14 daily 0.8 https://www.321223.com/cpzs/html/178.html 2026-11-10 00:53:54 daily 0.8 https://www.321223.com/cpzs/html/177.html 2026-11-10 00:53:34 daily 0.8 https://www.321223.com/cpzs/html/176.html 2026-11-10 00:53:14 daily 0.8 https://www.321223.com/cpzs/html/174.html 2026-11-10 00:52:54 daily 0.8 https://www.321223.com/cpzs/html/173.html 2026-11-10 00:52:34 daily 0.8 https://www.321223.com/cpzs/html/172.html 2026-11-10 00:52:14 daily 0.8 https://www.321223.com/cpzs/html/171.html 2026-11-10 00:51:54 daily 0.8 https://www.321223.com/cpzs/html/170.html 2026-11-10 00:51:34 daily 0.8 https://www.321223.com/cpzs/html/169.html 2026-11-10 00:51:14 daily 0.8 https://www.321223.com/cpzs/html/168.html 2026-11-10 00:50:54 daily 0.8 https://www.321223.com/cpzs/html/167.html 2026-11-10 00:50:34 daily 0.8 https://www.321223.com/cpzs/html/166.html 2026-11-10 00:50:14 daily 0.8 https://www.321223.com/cpzs/ 2026-11-10 00:49:54 daily 0.8 https://www.321223.com/cn/privacy-policy/ 2026-11-10 00:49:34 daily 0.8 https://www.321223.com/cn/pipeline/zevor-cel/ 2026-11-10 00:49:14 daily 0.8 https://www.321223.com/cn/pipeline/satri-cel/ 2026-11-10 00:48:54 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/kj-c2630/ 2026-11-10 00:48:34 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/kj-c2527/ 2026-11-10 00:48:14 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/kj-c2526/ 2026-11-10 00:47:54 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/ct1390b/ 2026-11-10 00:47:34 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/ct1190b-kj-c2219/ 2026-11-10 00:47:14 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/ct0596/ 2026-11-10 00:46:54 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/ 2026-11-10 00:46:34 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2635/ 2026-11-10 00:46:14 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2634/ 2026-11-10 00:45:54 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2633/ 2026-11-10 00:45:34 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2632/ 2026-11-10 00:45:14 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2529/ 2026-11-10 00:44:54 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/ 2026-11-10 00:44:34 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/car-t-cell-therapies/zevor-cel-ct053-3/ 2026-11-10 00:44:14 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/car-t-cell-therapies/ct041/ 2026-11-10 00:43:54 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/car-t-cell-therapies/ 2026-11-10 00:43:34 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/ 2026-11-10 00:43:14 daily 0.8 https://www.321223.com/cn/pipeline/expanded-access/ 2026-11-10 00:42:54 daily 0.8 https://www.321223.com/cn/pipeline/ 2026-11-10 00:42:34 daily 0.8 https://www.321223.com/cn/our-approach/technologies/ 2026-11-10 00:42:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=5 2026-11-10 00:41:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=4 2026-11-10 00:41:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=2 2026-11-10 00:41:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=1 2026-11-10 00:40:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/ 2026-11-10 00:40:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-κb-icam1-signaling/ 2026-11-10 00:40:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-��b-icam1-signaling/ 2026-11-10 00:39:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=5 2026-11-10 00:39:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=4 2026-11-10 00:39:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=2 2026-11-10 00:38:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=1 2026-11-10 00:38:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=4 2026-11-10 00:38:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=2 2026-11-10 00:37:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=1 2026-11-10 00:37:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/ 2026-11-10 00:37:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=5 2026-11-10 00:36:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=4 2026-11-10 00:36:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=2 2026-11-10 00:36:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=1 2026-11-10 00:35:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/ 2026-11-10 00:35:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=5 2026-11-10 00:35:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=4 2026-11-10 00:34:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=2 2026-11-10 00:34:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=1 2026-11-10 00:34:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/ 2026-11-10 00:33:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=5 2026-11-10 00:33:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=4 2026-11-10 00:33:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=2 2026-11-10 00:32:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=1 2026-11-10 00:32:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/ 2026-11-10 00:32:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=5 2026-11-10 00:31:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=4 2026-11-10 00:31:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=2 2026-11-10 00:31:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=1 2026-11-10 00:30:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/ 2026-11-10 00:30:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3ε-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ 2026-11-10 00:30:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3��-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ 2026-11-10 00:29:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=4 2026-11-10 00:29:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=2 2026-11-10 00:29:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=1 2026-11-10 00:28:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=5 2026-11-10 00:28:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=4 2026-11-10 00:28:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=2 2026-11-10 00:27:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=1 2026-11-10 00:27:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/ 2026-11-10 00:27:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/?page=5 2026-11-10 00:26:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/?page=4 2026-11-10 00:26:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/?page=3 2026-11-10 00:26:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/?page=2 2026-11-10 00:25:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/?page=1 2026-11-10 00:25:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20261001/ 2026-11-10 00:25:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20260918/?page=4 2026-11-10 00:24:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20260918/?page=2 2026-11-10 00:24:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20260918/?page=1 2026-11-10 00:24:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20260918/ 2026-11-10 00:23:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251029/?page=4 2026-11-10 00:23:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251029/?page=2 2026-11-10 00:23:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251029/?page=1 2026-11-10 00:22:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251029/ 2026-11-10 00:22:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251008/?page=4 2026-11-10 00:22:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251008/?page=2 2026-11-10 00:21:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251008/?page=1 2026-11-10 00:21:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251008/ 2026-11-10 00:21:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250930/?page=5 2026-11-10 00:20:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250930/?page=4 2026-11-10 00:20:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250930/?page=2 2026-11-10 00:20:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250930/?page=1 2026-11-10 00:19:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250930/ 2026-11-10 00:19:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250531/?page=5 2026-11-10 00:19:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250531/?page=4 2026-11-10 00:18:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250531/?page=2 2026-11-10 00:18:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250531/?page=1 2026-11-10 00:18:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250531/ 2026-11-10 00:17:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240524/?page=5 2026-11-10 00:17:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240524/?page=4 2026-11-10 00:17:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240524/?page=2 2026-11-10 00:16:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240524/?page=1 2026-11-10 00:16:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240524/ 2026-11-10 00:16:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240311/?page=4 2026-11-10 00:15:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240311/?page=2 2026-11-10 00:15:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240311/?page=1 2026-11-10 00:15:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240311/ 2026-11-10 00:14:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240205/?page=5 2026-11-10 00:14:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240205/?page=4 2026-11-10 00:14:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240205/?page=2 2026-11-10 00:13:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240205/?page=1 2026-11-10 00:13:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240205/ 2026-11-10 00:13:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230920/?page=5 2026-11-10 00:12:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230920/?page=4 2026-11-10 00:12:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230920/?page=2 2026-11-10 00:12:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230920/?page=1 2026-11-10 00:11:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230920/ 2026-11-10 00:11:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230909/?page=5 2026-11-10 00:11:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230909/?page=4 2026-11-10 00:10:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230909/?page=2 2026-11-10 00:10:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230909/?page=1 2026-11-10 00:10:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230909/ 2026-11-10 00:09:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230830/?page=4 2026-11-10 00:09:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230830/?page=2 2026-11-10 00:09:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230830/?page=1 2026-11-10 00:08:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230830/ 2026-11-10 00:08:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20221215/?page=5 2026-11-10 00:08:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20221215/?page=4 2026-11-10 00:07:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20221215/?page=2 2026-11-10 00:07:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20221215/?page=1 2026-11-10 00:07:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20221215/ 2026-11-10 00:06:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20220817/?page=4 2026-11-10 00:06:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20220817/?page=2 2026-11-10 00:06:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20220817/?page=1 2026-11-10 00:05:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20220817/ 2026-11-10 00:05:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20201001/?page=5 2026-11-10 00:05:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20201001/?page=4 2026-11-10 00:04:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20201001/?page=2 2026-11-10 00:04:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20201001/?page=1 2026-11-10 00:04:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20201001/ 2026-11-10 00:03:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200925/?page=5 2026-11-10 00:03:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200925/?page=4 2026-11-10 00:03:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200925/?page=2 2026-11-10 00:02:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200925/?page=1 2026-11-10 00:02:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200925/ 2026-11-10 00:02:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200801/?page=5 2026-11-10 00:01:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200801/?page=4 2026-11-10 00:01:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200801/?page=2 2026-11-10 00:01:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200801/?page=1 2026-11-10 00:00:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200801/ 2026-11-10 00:00:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200121/?page=5 2026-11-10 00:00:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200121/?page=4 2026-11-09 23:59:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200121/?page=2 2026-11-09 23:59:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200121/?page=1 2026-11-09 23:59:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200121/ 2026-11-09 23:58:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20191219/?page=5 2026-11-09 23:58:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20191219/?page=4 2026-11-09 23:58:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20191219/?page=2 2026-11-09 23:57:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20191219/?page=1 2026-11-09 23:57:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20191219/ 2026-11-09 23:57:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190920/?page=5 2026-11-09 23:56:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190920/?page=4 2026-11-09 23:56:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190920/?page=2 2026-11-09 23:56:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190920/?page=1 2026-11-09 23:55:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190920/ 2026-11-09 23:55:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190701/?page=4 2026-11-09 23:55:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190701/?page=2 2026-11-09 23:54:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190701/?page=1 2026-11-09 23:54:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190701/ 2026-11-09 23:54:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190429/?page=5 2026-11-09 23:53:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190429/?page=4 2026-11-09 23:53:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190429/?page=2 2026-11-09 23:53:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190429/?page=1 2026-11-09 23:52:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190429/ 2026-11-09 23:52:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190417/?page=4 2026-11-09 23:52:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190417/?page=2 2026-11-09 23:51:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190417/?page=1 2026-11-09 23:51:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190417/ 2026-11-09 23:51:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181101/?page=5 2026-11-09 23:50:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181101/?page=4 2026-11-09 23:50:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181101/?page=2 2026-11-09 23:50:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181101/?page=1 2026-11-09 23:49:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181101/ 2026-11-09 23:49:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181001/?page=4 2026-11-09 23:49:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181001/?page=2 2026-11-09 23:48:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181001/?page=1 2026-11-09 23:48:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181001/ 2026-11-09 23:48:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180906/?page=4 2026-11-09 23:47:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180906/?page=2 2026-11-09 23:47:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180906/?page=1 2026-11-09 23:47:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180906/ 2026-11-09 23:46:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180804/?page=4 2026-11-09 23:46:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180804/?page=2 2026-11-09 23:46:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180804/?page=1 2026-11-09 23:45:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180804/ 2026-11-09 23:45:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20171218/?page=5 2026-11-09 23:45:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20171218/?page=4 2026-11-09 23:44:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20171218/?page=2 2026-11-09 23:44:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20171218/?page=1 2026-11-09 23:44:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20171218/ 2026-11-09 23:43:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170919/?page=5 2026-11-09 23:43:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170919/?page=4 2026-11-09 23:43:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170919/?page=2 2026-11-09 23:42:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170919/?page=1 2026-11-09 23:42:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170919/ 2026-11-09 23:42:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170703/?page=5 2026-11-09 23:41:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170703/?page=4 2026-11-09 23:41:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170703/?page=2 2026-11-09 23:41:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170703/?page=1 2026-11-09 23:40:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170703/ 2026-11-09 23:40:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170516/?page=4 2026-11-09 23:40:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170516/?page=2 2026-11-09 23:39:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170516/?page=1 2026-11-09 23:39:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170516/ 2026-11-09 23:39:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20161229/?page=4 2026-11-09 23:38:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/20161229/?page=2 2026-11-09 23:38:34 daily 0.8 https://www.321223.com/cn/our-approach/publications/20161229/?page=1 2026-11-09 23:38:14 daily 0.8 https://www.321223.com/cn/our-approach/publications/20161229/ 2026-11-09 23:37:54 daily 0.8 https://www.321223.com/cn/our-approach/publications/ 2026-11-09 23:37:14 daily 0.8 https://www.321223.com/cn/our-approach/manufacturing/ 2026-11-09 23:36:54 daily 0.8 https://www.321223.com/cn/our-approach/ 2026-11-09 23:36:34 daily 0.8 https://www.321223.com/cn/news/Z6尊龙凯时药业美国cgmp出产工厂实现首例car-t产品的临床批次出产/ 2026-11-09 23:36:14 daily 0.8 https://www.321223.com/cn/news/Z6尊龙凯时药业bcma-car-t泽沃基奥仑赛注射液-ct053-新药上市申请获国度药监局受理/ 2026-11-09 23:35:54 daily 0.8 https://www.321223.com/cn/news/?page=4 2026-11-09 23:35:34 daily 0.8 https://www.321223.com/cn/news/?page=3 2026-11-09 23:35:14 daily 0.8 https://www.321223.com/cn/news/?page=21 2026-11-09 23:34:54 daily 0.8 https://www.321223.com/cn/news/?page=20 2026-11-09 23:34:34 daily 0.8 https://www.321223.com/cn/news/?page=2 2026-11-09 23:34:14 daily 0.8 https://www.321223.com/cn/news/?page=19 2026-11-09 23:33:54 daily 0.8 https://www.321223.com/cn/news/?page=18 2026-11-09 23:33:34 daily 0.8 https://www.321223.com/cn/news/?page=1 2026-11-09 23:33:14 daily 0.8 https://www.321223.com/cn/news/20261009/ 2026-11-09 23:32:54 daily 0.8 https://www.321223.com/cn/news/20260929/ 2026-11-09 23:32:34 daily 0.8 https://www.321223.com/cn/news/20260921/ 2026-11-09 23:32:14 daily 0.8 https://www.321223.com/cn/news/20260914/ 2026-11-09 23:31:54 daily 0.8 https://www.321223.com/cn/news/20260819/ 2026-11-09 23:31:34 daily 0.8 https://www.321223.com/cn/news/20260807/ 2026-11-09 23:31:14 daily 0.8 https://www.321223.com/cn/news/20260804/ 2026-11-09 23:30:54 daily 0.8 https://www.321223.com/cn/news/20260724/ 2026-11-09 23:30:34 daily 0.8 https://www.321223.com/cn/news/20260722/ 2026-11-09 23:30:14 daily 0.8 https://www.321223.com/cn/news/20260716/ 2026-11-09 23:29:54 daily 0.8 https://www.321223.com/cn/news/20260715/ 2026-11-09 23:29:34 daily 0.8 https://www.321223.com/cn/news/20260707/ 2026-11-09 23:29:14 daily 0.8 https://www.321223.com/cn/news/20260622/ 2026-11-09 23:28:54 daily 0.8 https://www.321223.com/cn/news/20260622-1/ 2026-11-09 23:28:34 daily 0.8 https://www.321223.com/cn/news/20260615/ 2026-11-09 23:28:14 daily 0.8 https://www.321223.com/cn/news/20260601/ 2026-11-09 23:27:54 daily 0.8 https://www.321223.com/cn/news/20260521/ 2026-11-09 23:27:34 daily 0.8 https://www.321223.com/cn/news/20260512/ 2026-11-09 23:27:14 daily 0.8 https://www.321223.com/cn/news/20260429/ 2026-11-09 23:26:54 daily 0.8 https://www.321223.com/cn/news/20260428/ 2026-11-09 23:26:34 daily 0.8 https://www.321223.com/cn/news/20260309/ 2026-11-09 23:26:14 daily 0.8 https://www.321223.com/cn/news/20260306/ 2026-11-09 23:25:54 daily 0.8 https://www.321223.com/cn/news/20260213/ 2026-11-09 23:25:34 daily 0.8 https://www.321223.com/cn/news/20260112/ 2026-11-09 23:25:14 daily 0.8 https://www.321223.com/cn/news/20251230/ 2026-11-09 23:24:54 daily 0.8 https://www.321223.com/cn/news/20251229/ 2026-11-09 23:24:34 daily 0.8 https://www.321223.com/cn/news/20251208/ 2026-11-09 23:24:14 daily 0.8 https://www.321223.com/cn/news/20251207/ 2026-11-09 23:23:54 daily 0.8 https://www.321223.com/cn/news/20251120/ 2026-11-09 23:23:34 daily 0.8 https://www.321223.com/cn/news/20251119/ 2026-11-09 23:23:14 daily 0.8 https://www.321223.com/cn/news/20250626/ 2026-11-09 23:22:54 daily 0.8 https://www.321223.com/cn/news/20250625/ 2026-11-09 23:22:34 daily 0.8 https://www.321223.com/cn/news/20250617/ 2026-11-09 23:22:14 daily 0.8 https://www.321223.com/cn/news/20250113/ 2026-11-09 23:21:54 daily 0.8 https://www.321223.com/cn/news/20220921/ 2026-11-09 23:21:34 daily 0.8 https://www.321223.com/cn/news/20190129/ 2026-11-09 23:21:14 daily 0.8 https://www.321223.com/cn/news/20180302/ 2026-11-09 23:20:54 daily 0.8 https://www.321223.com/cn/news/20170830/ 2026-11-09 23:20:34 daily 0.8 https://www.321223.com/cn/news/20170810/ 2026-11-09 23:20:14 daily 0.8 https://www.321223.com/cn/news/20170731/ 2026-11-09 23:19:54 daily 0.8 https://www.321223.com/cn/news/20170630/ 2026-11-09 23:19:34 daily 0.8 https://www.321223.com/cn/news/20170503/ 2026-11-09 23:19:14 daily 0.8 https://www.321223.com/cn/news/20160921/ 2026-11-09 23:18:54 daily 0.8 https://www.321223.com/cn/news/20160125/ 2026-11-09 23:18:34 daily 0.8 https://www.321223.com/cn/news/ 2026-11-09 23:18:14 daily 0.8 https://www.321223.com/cn/investors/listing-documents/ 2026-11-09 23:17:54 daily 0.8 https://www.321223.com/cn/investors/ir-contact/ 2026-11-09 23:17:34 daily 0.8 https://www.321223.com/cn/investors/financial-reports/ 2026-11-09 23:17:14 daily 0.8 https://www.321223.com/cn/investors/corporate-governance/ 2026-11-09 23:16:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=6 2026-11-09 23:16:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=5 2026-11-09 23:16:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=4 2026-11-09 23:15:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=3 2026-11-09 23:15:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=2 2026-11-09 23:15:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=1 2026-11-09 23:14:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/ 2026-11-09 23:14:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/通用型car-t产品ct0596及ct1190b的积极临床数据/ 2026-11-09 23:14:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/ͨ����car-t��Ʒct0596��ct1190b�Ļ����ٴ�����/ 2026-11-09 23:13:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=6 2026-11-09 23:13:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=5 2026-11-09 23:13:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=4 2026-11-09 23:12:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=3 2026-11-09 23:12:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=2 2026-11-09 23:12:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=1 2026-11-09 23:11:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=6 2026-11-09 23:11:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=5 2026-11-09 23:11:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=4 2026-11-09 23:10:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=3 2026-11-09 23:10:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=2 2026-11-09 23:10:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=1 2026-11-09 23:09:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/ 2026-11-09 23:09:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=6 2026-11-09 23:09:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=5 2026-11-09 23:08:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=4 2026-11-09 23:08:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=3 2026-11-09 23:08:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=2 2026-11-09 23:07:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=1 2026-11-09 23:07:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/ 2026-11-09 23:07:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=6 2026-11-09 23:06:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=5 2026-11-09 23:06:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=4 2026-11-09 23:06:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=3 2026-11-09 23:05:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=2 2026-11-09 23:05:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=1 2026-11-09 23:05:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/ 2026-11-09 23:04:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=6 2026-11-09 23:04:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=5 2026-11-09 23:04:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=4 2026-11-09 23:03:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=3 2026-11-09 23:03:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=2 2026-11-09 23:03:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=1 2026-11-09 23:02:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/ 2026-11-09 23:02:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=6 2026-11-09 23:02:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=5 2026-11-09 23:01:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=4 2026-11-09 23:01:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=3 2026-11-09 23:01:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=2 2026-11-09 23:00:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=1 2026-11-09 23:00:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/ 2026-11-09 23:00:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=6 2026-11-09 22:59:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=5 2026-11-09 22:59:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=4 2026-11-09 22:59:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=3 2026-11-09 22:58:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=2 2026-11-09 22:58:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=1 2026-11-09 22:58:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/ 2026-11-09 22:57:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 2026-11-09 22:57:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-09 22:57:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-09 22:56:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-09 22:56:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-09 22:56:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-09 22:55:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-09 22:55:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=5 2026-11-09 22:55:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=4 2026-11-09 22:54:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=3 2026-11-09 22:54:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=2 2026-11-09 22:54:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=1 2026-11-09 22:53:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/ 2026-11-09 22:53:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=6 2026-11-09 22:53:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=5 2026-11-09 22:52:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=4 2026-11-09 22:52:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=3 2026-11-09 22:52:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=2 2026-11-09 22:51:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=1 2026-11-09 22:51:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/ 2026-11-09 22:51:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-asco-claudin18-2-specific-car-t-cells-satri-cel-versus-treatment-of-physician-s-choice-tpc-for-previously-treated-advanced-gastric-or-gastroesophageal-junction-cancer-g-gejc-primary-results-from-a-randomized-open-label-phase-ii-trial-c/ 2026-11-09 22:50:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=5 2026-11-09 22:50:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=4 2026-11-09 22:50:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=3 2026-11-09 22:49:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=2 2026-11-09 22:49:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=1 2026-11-09 22:49:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/ 2026-11-09 22:48:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 2026-11-09 22:48:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-09 22:48:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-09 22:47:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-09 22:47:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-09 22:47:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-09 22:46:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-09 22:46:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=6 2026-11-09 22:46:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=5 2026-11-09 22:45:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=4 2026-11-09 22:45:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=3 2026-11-09 22:45:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=2 2026-11-09 22:44:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=1 2026-11-09 22:44:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/ 2026-11-09 22:44:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=6 2026-11-09 22:43:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=5 2026-11-09 22:43:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=4 2026-11-09 22:43:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=3 2026-11-09 22:42:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=2 2026-11-09 22:42:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=1 2026-11-09 22:42:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/ 2026-11-09 22:41:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=6 2026-11-09 22:41:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=5 2026-11-09 22:41:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=4 2026-11-09 22:40:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=3 2026-11-09 22:40:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=2 2026-11-09 22:40:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=1 2026-11-09 22:39:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/ 2026-11-09 22:39:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=5 2026-11-09 22:39:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=4 2026-11-09 22:38:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=3 2026-11-09 22:38:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=2 2026-11-09 22:38:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=1 2026-11-09 22:37:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/ 2026-11-09 22:37:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=6 2026-11-09 22:37:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=5 2026-11-09 22:36:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=4 2026-11-09 22:36:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=3 2026-11-09 22:36:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=2 2026-11-09 22:35:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=1 2026-11-09 22:35:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/ 2026-11-09 22:35:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=5 2026-11-09 22:34:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=4 2026-11-09 22:34:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=3 2026-11-09 22:34:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=2 2026-11-09 22:33:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=1 2026-11-09 22:33:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/ 2026-11-09 22:33:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=6 2026-11-09 22:32:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=5 2026-11-09 22:32:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=4 2026-11-09 22:32:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=3 2026-11-09 22:31:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=2 2026-11-09 22:31:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=1 2026-11-09 22:31:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/ 2026-11-09 22:30:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-gi-a-multicenter-phase-1-study-of-ab011-a-recombinant-humanized-anti-cldn18-2-monoclonal-antibody-ab011-as-monotherapy-and-combined-with-capecitabine-and-oxaliplatin-capox-in-patients-with-advanced-solid-tumors/ 2026-11-09 22:30:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=5 2026-11-09 22:30:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=4 2026-11-09 22:29:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=3 2026-11-09 22:29:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=2 2026-11-09 22:29:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=1 2026-11-09 22:28:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/ 2026-11-09 22:28:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=5 2026-11-09 22:28:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=4 2026-11-09 22:27:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=3 2026-11-09 22:27:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=2 2026-11-09 22:27:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=1 2026-11-09 22:26:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/ 2026-11-09 22:26:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=6 2026-11-09 22:26:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=5 2026-11-09 22:25:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=4 2026-11-09 22:25:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=3 2026-11-09 22:25:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=2 2026-11-09 22:24:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=1 2026-11-09 22:24:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/ 2026-11-09 22:24:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=6 2026-11-09 22:23:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=5 2026-11-09 22:23:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=4 2026-11-09 22:23:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=3 2026-11-09 22:22:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=2 2026-11-09 22:22:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=1 2026-11-09 22:22:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/ 2026-11-09 22:21:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-09 22:21:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-09 22:21:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-09 22:20:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-09 22:20:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-09 22:20:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-09 22:19:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=5 2026-11-09 22:19:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=4 2026-11-09 22:19:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=3 2026-11-09 22:18:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=2 2026-11-09 22:18:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=1 2026-11-09 22:18:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/ 2026-11-09 22:17:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=5 2026-11-09 22:17:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=4 2026-11-09 22:17:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=3 2026-11-09 22:16:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=2 2026-11-09 22:16:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=1 2026-11-09 22:16:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/ 2026-11-09 22:15:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=6 2026-11-09 22:15:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=5 2026-11-09 22:15:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=4 2026-11-09 22:14:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=3 2026-11-09 22:14:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=2 2026-11-09 22:14:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=1 2026-11-09 22:13:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/ 2026-11-09 22:13:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=5 2026-11-09 22:13:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=4 2026-11-09 22:12:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=3 2026-11-09 22:12:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=2 2026-11-09 22:12:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=1 2026-11-09 22:11:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/ 2026-11-09 22:11:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=5 2026-11-09 22:11:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=4 2026-11-09 22:10:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=3 2026-11-09 22:10:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=2 2026-11-09 22:10:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=1 2026-11-09 22:09:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/ 2026-11-09 22:09:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=5 2026-11-09 22:09:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=4 2026-11-09 22:08:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=3 2026-11-09 22:08:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=2 2026-11-09 22:08:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=1 2026-11-09 22:07:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/ 2026-11-09 22:07:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=6 2026-11-09 22:07:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=5 2026-11-09 22:06:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=4 2026-11-09 22:06:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=3 2026-11-09 22:06:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=2 2026-11-09 22:05:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=1 2026-11-09 22:05:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/ 2026-11-09 22:05:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=5 2026-11-09 22:04:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=4 2026-11-09 22:04:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=3 2026-11-09 22:04:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=2 2026-11-09 22:03:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=1 2026-11-09 22:03:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/ 2026-11-09 22:03:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=5 2026-11-09 22:02:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=4 2026-11-09 22:02:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=3 2026-11-09 22:02:14 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=2 2026-11-09 22:01:54 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=1 2026-11-09 22:01:34 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/ 2026-11-09 22:01:14 daily 0.8 https://www.321223.com/cn/investors/announcements-circulars/ 2026-11-09 22:00:54 daily 0.8 https://www.321223.com/cn/investors/ 2026-11-09 22:00:34 daily 0.8 https://www.321223.com/cn/disclaimer/ 2026-11-09 22:00:14 daily 0.8 https://www.321223.com/cn/contact-us/ 2026-11-09 21:59:54 daily 0.8 https://www.321223.com/cn/careers/join-us/ 2026-11-09 21:59:34 daily 0.8 https://www.321223.com/cn/careers/ 2026-11-09 21:59:14 daily 0.8 https://www.321223.com/cn/about-us/vision-mission-values/ 2026-11-09 21:58:54 daily 0.8 https://www.321223.com/cn/about-us/partnering/ 2026-11-09 21:58:34 daily 0.8 https://www.321223.com/cn/about-us/leadership/ 2026-11-09 21:58:14 daily 0.8 https://www.321223.com/cn/about-us/company-overview/ 2026-11-09 21:57:54 daily 0.8 https://www.321223.com/cn/about-us/ 2026-11-09 21:57:34 daily 0.8 https://www.321223.com/cn/" 2026-11-09 21:57:14 daily 0.8 https://www.321223.com/cn/ 2026-11-09 21:56:54 daily 0.8 https://www.321223.com/ 2026-11-09 21:56:34 daily 0.8 https://www.321223.com" 2026-11-09 21:56:14 daily 0.8 https://www.321223.com 2026-11-09 21:55:54 daily 0.8 http://www.321223.com<#if 2026-11-09 21:55:34 daily 0.8 http://www.321223.com/html/web/xinwenzhongxin/shipinzhuanqu/index.html 2026-11-09 21:55:14 daily 0.8 http://www.321223.com/html/web/xinwenzhongxin/fangdaxinwen/index.html 2026-11-09 21:54:54 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/index.html 2026-11-09 21:54:34 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2103055327044489218.html 2026-11-09 21:54:14 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2102682494330130434.html 2026-11-09 21:53:54 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/zhongxingshangye/index.html 2026-11-09 21:53:34 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/yihangkeji/index.html 2026-11-09 21:53:14 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/xinshengfeixiang/index.html 2026-11-09 21:52:54 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/shouhangzhishengji/index.html 2026-11-09 21:52:34 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/index.html 2026-11-09 21:52:14 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/haihangkonggu/index.html 2026-11-09 21:51:54 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/fangdategang/index.html 2026-11-09 21:51:34 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/fangdatansu/index.html 2026-11-09 21:51:14 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/dongbeizhiyao/index.html 2026-11-09 21:50:54 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/chengdutancai/index.html 2026-11-09 21:50:34 daily 0.8 http://www.321223.com/html/web/shehuizeren/zhichiguofang/index.html 2026-11-09 21:50:14 daily 0.8 http://www.321223.com/html/web/shehuizeren/yifanashui/index.html 2026-11-09 21:49:54 daily 0.8 http://www.321223.com/html/web/shehuizeren/shehuigongyi/index.html 2026-11-09 21:49:34 daily 0.8 http://www.321223.com/html/web/shehuizeren/jienenghuanbao/index.html 2026-11-09 21:49:14 daily 0.8 http://www.321223.com/html/web/shehuizeren/baozhangjiuye/index.html 2026-11-09 21:48:54 daily 0.8 http://www.321223.com/html/web/rencaifazhan/zhaopingonggao/index.html 2026-11-09 21:48:34 daily 0.8 http://www.321223.com/html/web/guanyuwomen/zuzhijiagou/index.html 2026-11-09 21:48:14 daily 0.8 http://www.321223.com/html/web/guanyuwomen/fazhanlicheng/index.html 2026-11-09 21:47:54 daily 0.8 http://www.321223.com/html/web/guanyuwomen/fangdarongyu/index.html 2026-11-09 21:47:34 daily 0.8 http://www.321223.com/html/web/guanyuwomen/fangdajianjie/index.html 2026-11-09 21:47:14 daily 0.8 http://www.321223.com/html/web/dangjianwenhua/xingfufangda/index.html 2026-11-09 21:46:54 daily 0.8 http://www.321223.com/html/web/dangjianwenhua/qiyelinian/index.html 2026-11-09 21:46:34 daily 0.8 http://www.321223.com/html/web/dangjianwenhua/dangqunhuodong/index.html 2026-11-09 21:46:14 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/yiyao/index.html 2026-11-09 21:45:54 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/index.html 2026-11-09 21:45:34 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ https:/www.cdcarbon.cn/intro/3.html 2026-11-09 21:45:14 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ https:/www.cd-ts.cn/about/7.html 2026-11-09 21:44:54 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ https:/fushuncarbon.com 2026-11-09 21:44:34 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ http:/fdtsgs.com 2026-11-09 21:44:14 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952972548200914946.html 2026-11-09 21:43:54 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952971930770006018.html 2026-11-09 21:43:34 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952969997875339266.html 2026-11-09 21:43:14 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952966690133958658.html 2026-11-09 21:42:54 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/shangye/index.html 2026-11-09 21:42:34 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/hangkong/index.html 2026-11-09 21:42:14 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/index.html 2026-11-09 21:41:54 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ https:/www.jxfangda-steels.com/index/about/id/1.html 2026-11-09 21:41:34 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ https:/www.fddzsteel.com/dg_gywm/dg_qyjj/cindex1.html 2026-11-09 21:41:14 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ http:/www.scdesheng.com/ 2026-11-09 21:40:54 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ http:/www.nhi.com.cn/html/web/guanyuwomen/gongsijianjie/index.html 2026-11-09 21:40:34 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ http:/www.fangda-specialsteels.com/web/index.aspx 2026-11-09 21:40:14 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/2062069973823197186.html 2026-11-09 21:39:54 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952982209025204225.html 2026-11-09 21:39:34 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952981773291544577.html 2026-11-09 21:39:14 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952981140610146305.html 2026-11-09 21:38:54 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952980763097620482.html 2026-11-09 21:38:34 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952980411455561730.html 2026-11-09 21:38:14 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952980023696351234.html 2026-11-09 21:37:54 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952978003895705602.html 2026-11-09 21:37:34 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952977484364046338.html 2026-11-09 21:37:14 daily 0.8 http://www.321223.com/column/95/ 2026-11-09 21:36:54 daily 0.8 http://www.321223.com/column/94/ 2026-11-09 21:36:34 daily 0.8 http://www.321223.com/column/92/ 2026-11-09 21:36:14 daily 0.8 http://www.321223.com/column/138/ 2026-11-09 21:35:54 daily 0.8 http://www.321223.com/ 2026-11-09 21:35:34 daily 0.8 http://www.321223.com https://www.yzr.com.cn/micro/main/aboutus/63ca0a89b5240a7602621d60 2026-11-09 21:35:14 daily 0.8 http://www.321223.com https://www.ykfdyy.com/ 2026-11-09 21:34:54 daily 0.8 http://www.321223.com https://www.westair.cn/stcontent/menupage/f9515923-5f75-4801-a3f3-daf09cdbb133/fd170793-0f42-499e-b03a-bc0632fe0cc5/9f991f7f-89e1-4c22-b1c7-411156b46ef0 2026-11-09 21:34:34 daily 0.8 http://www.321223.com https://www.urumqi-air.com/micro/main/aboutus/641159f50c682c7801e5a149 2026-11-09 21:34:14 daily 0.8 http://www.321223.com https://www.tjys.com.cn/html/web/guanyuyihang/gongsijianjie/index.html 2026-11-09 21:33:54 daily 0.8 http://www.321223.com https://www.tianjin-air.com/stcontent/menupage/0bbd75f1-bc38-41c6-95f4-4e3644aa70b8/7c0ff667-57c6-4de5-8e7f-e9fa5b0d4ccb/766eab66-6b64-48f7-b6de-b2ab8c2e8742 2026-11-09 21:33:34 daily 0.8 http://www.321223.com https://www.nepharm.com.cn/html/web/liaojiewomen/gongsijianjie/index.html 2026-11-09 21:33:14 daily 0.8 http://www.321223.com https://www.luckyair.net/micro/main/aboutus/641d4bbf230c607e69a9a99f 2026-11-09 21:32:54 daily 0.8 http://www.321223.com https://www.jdair.net/micro/main/article/64599c7160a9be4d4434c960 2026-11-09 21:32:34 daily 0.8 http://www.321223.com https://www.hnasatc.edu.cn/xxgk/xxjj.htm 2026-11-09 21:32:14 daily 0.8 http://www.321223.com https://www.hnair.com/guanyuhaihang/hhgs/gsjj/ 2026-11-09 21:31:54 daily 0.8 http://www.321223.com https://www.hnacargo.com/Portal2/AboutUs.aspx 2026-11-09 21:31:34 daily 0.8 http://www.321223.com https://www.gxairlines.com/stdair/tcms?directoryName=foot&fileName=CompanyAndOverview 2026-11-09 21:31:14 daily 0.8 http://www.321223.com https://www.fuzhou-air.cn/micro/main/aboutus/63db6994257effa4641ba390 2026-11-09 21:30:54 daily 0.8 http://www.321223.com https://www.fd-yy.com/html/web/guanyuwomen/yiyuanjianjie/index.html 2026-11-09 21:30:34 daily 0.8 http://www.321223.com https://www.deerjet.com/about/advantage.html 2026-11-09 21:30:14 daily 0.8 http://www.321223.com https://www.airchangan.com/content/c2aafb9c-c9a1-414e-8182-000a082ff315 2026-11-09 21:29:54 daily 0.8 http://www.321223.com http://www.zxbusiness.com/web/gyzx?nid=1 2026-11-09 21:29:34 daily 0.8 http://www.321223.com http://www.hnatechnic.com/html/web/aboutus/gongsijianjie/index.html 2026-11-09 21:29:14 daily 0.8 http://www.321223.com http://www.3-hospital-cqmu.com 2026-11-09 21:28:54 daily 0.8 http://www.321223.com /html/web/chengyuandanwei/hangkong/1953010391426195457.html 2026-11-09 21:28:34 daily 0.8 http://www.321223.com /html/web/chengyuandanwei/hangkong/1953007446785712129.html 2026-11-09 21:28:14 daily 0.8 http://www.321223.com 2026-11-09 21:27:54 daily 0.8 https://jhrr3q.321223.com 2026-11-09 21:04:15 daily 0.8